Navigation Links
HIV positive and HIV negative patients have similar survival rates following liver transplant
Date:4/24/2009

Copenhagen, Denmark, Friday 24 April: HIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark.

The study results showed no difference in survival rates at 1 and 5 years between HIV negative and HIV positive patients (86.5% and 74% versus 87.1% and 78%, p=0.843), suggesting a good prognosis for HIV positive patients following liver transplant. However, the study confirmed that co-infection with hepatitis C virus (HCV) is a significant predictor of poorer survival rates in patients with HIV. Survival rates at 1 and 5 years were 73% and 53% in HIV positive patients with hepatitis C versus 87% and 69% (p=0.047) in HIV negative patients with hepatitis C.

Doctor Kosh Agarwal, of the Institute of Liver Studies, Kings College Hospital, London, who led the study said: "Data on long term outcomes from liver transplantation in HIV patients is limited. These study results are valuable confirmation that selected HIV positive patients are as suitable candidates for liver transplant as HIV negative patients and should have similar access to treatment. However, those patients with co-infection with hepatitis C did less well, emphasising the need for appropriate antiviral therapy early in the course of their HCV related liver disease. In the context of co-infection, these data emphasise the need to develop newer and more innovative treatment strategies. These should include exposure to new small molecule therapies for HCV that are currently being explored in mono-infection."

The researchers conducted a prospective analysis of the UK Transplant Database to determine the long-term outcomes in HIV patients undergoing liver transplant in the UK. They examined 6,315 adult patients (>18 years) undergoing their first liver transplant between March 1994 and April 2008
'/>"/>

Contact: Camilla Dormer
easlpressoffice@cohnwolfe.com
44-078-761-90439
European Association for the Study of the Liver
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. The ALS Association's 'ALS Across America' Focuses On Staying Positive and Involved
2. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
3. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
4. Economy Got You Down? Use The Principles Of Positive Psychology
5. Standard and Poors Raises Boston Scientifics Rating Outlook to Positive
6. Recent Industry Developments Reaffirm Positive Glucose Industry Outlook
7. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
8. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
9. Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)
10. Positive behavior support training curriculum
11. CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... (May 22, 2012) Scientists at Virginia Commonwealth ... closer to developing a new therapy for acute ... agents obatoclax and sorafenib kill leukemia cells much ... are administered individually., Recently published in the journal ... Steven Grant, M.D., Shirley Carter Olsson and Sture ...
(Date:5/22/2012)... 2012) Pushed to the brink of survival, the ... ancient system that has helped organisms cope with internal ... an integral part of this system, heat shock protein ... accommodate the genetic changes and profound disturbances in normal ... theorized that inhibiting HSP90 just might render breast cancer ...
(Date:5/22/2012)... PORTLAND, Ore. Women who are unable to ... lung function of their newborns by taking Vitamin ... Oregon Health & Science University Doernbecher Children,s Hospital. ... affect the lung development of the developing baby, ... risk of asthma," said Cindy McEvoy, M.D., M.C.R., ...
(Date:5/22/2012)... May 22 (HealthDay News) -- The number of liver ... a new study finds. Researchers said one reason ... death has become more commonplace, and many of those ... organs aren,t healthy enough to attempt a transplant. Another ... to a condition known as fatty liver disease, which ...
(Date:5/22/2012)... microfluidic chip to test for latent tuberculosis. They hope ... than current testing for the disease. , "Our assay ... said Ying Liu, a research specialist working with Professor ... Engineering. , The team has already conducted testing of ... States. , About one-third of the world,s population is ...
Breaking Medicine News(10 mins):Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 3Health News:Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy 2Health News:Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy 3Health News:Vitamin C improves lung function in newborns of pregnant smoking women 2Health News:U.S. Liver Transplants Declining 2Health News:New TB test promises to be cheap and fast 2
... Researchers in Germany have developed a new risk assessment ... and patient's risk of cardiac death. , ECG is ... death can be determined and analysed by the computer.The ... to be calculated.// When the programme has completed its ...
... Researchers in France say that the distorting spectacles can ... balance. They think that the spectacles reset the patient's ... to a long-lasitng cure for some postural problems. ... hemisphere may suffer paralysis down their left side and ...
... of starch, previously thought to be just 'empty calories', actually ... Research Organisation (CSIRO), researchers have revealed that resistant starch could ... cancer. , , ... and China have low rates of bowel cancer even though ...
... has now been developed, which makes the process of providing ... , , The device, called Percutaneous ... involves giving artificial respiration to critically ill patients.// , ... the wall of the trachea,the passage leading to the lungs, ...
... is linked with deliquent behaviour of the chilren later ... Delaney-Black, of Children's Hospital of Michigan, the co author ... in comparison to the teetotallers ,women who drank the ... three times more likely to have a child diagnosed ...
... by the National Institutes of Health, showed that at-risk ... reduced their risk of diabetes by 58%, even without ... type 2 diabetes can sharply reduce the odds through ... data from the nation's first major clinical trial to ...
Other Medicine News:
(Date:5/22/2012)... May 22, 2012 Sorbent Therapeutics, Inc. ... renal diseases, presented positive data from its Phase ... of 111 heart failure patients with chronic kidney ... as compared to placebo.    Data ... presented in an oral session at the Annual ...
(Date:5/22/2012)... 22, 2012   AMRI (NASDAQ: ... organization, announced today the appointment of Ian Shott as ... chairman, president and CEO. In this newly created role, ... in Europe, including the company,s site in Wales, United ... team. As the founder of Excelsyn, acquired by AMRI ...
(Date:5/22/2012)... Inc. and AB SCIEX announced today that they have ... Dr. Gary Van Berkel and his colleagues of Oak ... innovator in the field of mass spectrometry and is ... the field.  The agreement provides Prosolia a license to ... based on the liquid micro- junction surface sampling probe ...
Breaking Medicine Technology:Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 2Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 3AMRI Announces President for AMRI Europe 2AMRI Announces President for AMRI Europe 3Prosolia and AB SCIEX reach licensing agreement 2Obese Drivers Less Likely to Buckle Up 3A Study 90693 1Obese Drivers Less Likely to Buckle Up 3A Study 90693 2HPV vaccine completion rate among girls is poor getting worse 90691 1HPV vaccine completion rate among girls is poor getting worse 90691 2HPV vaccine completion rate among girls is poor getting worse 90691 3New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease 25324 1New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease 25324 2
... Ill., March 29, 2007 /PRNewswire-FirstCall/ -- Baxter,International Inc. ... investigational pandemic H5N1 influenza vaccine and,plans to initiate ... in Europe to confirm the study results. , ... candidate,vaccine is highly immunogenic at low doses, and ...
... Valortim-Treated,Animals , PRINCETON, N.J. and ANNAPOLIS, MD., ... a leading monoclonal antibody company, and,PharmAthene, Inc., ... development of biodefense countermeasures, today announced,that Valortim, ... developed for the prevention and treatment of ...
Other Medicine Technology:Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 2Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 3Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7
Angled 30 degree shaft. 13 mm from tip to bend with 2.5 mm hook curved tip. Polished finished. Overall length excluding hub: 35 mm, 1.4 inches....
Binkhorst, length 18 mm....
Army/Navy retractor (set of 2)....
Sharp. 4 mm wide. Hand-Held...
Medicine Products: